BOSTON SCIENTIFIC CORP (BSX) Stock Analysis

Analysis from 10-Q filed 2025-11-03. Data as of Q2 2026.

Overall Grade: F (Concerning)

Grade F (Concerning). ROIC 11.0%. FCF margin 17.3%. D/E 0.5x. Source: 10-Q filed 2025-11-03.

Metric	Value	Context
ROIC	11.0%	Near cost of capital
FCF Margin	17.3%	Strong cash generation
Debt/Equity	0.5x	Moderate leverage

ROIC 11.0% — Top 25% of sector peers. FCF margin 17.3% — Top 5%.

Explore BOSTON SCIENTIFIC CORP: Earnings History | Filings

Programmatic access: Available via MCP at mcp.metricduck.com. Tools for BSX: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.

---

Profitability: BOSTON SCIENTIFIC CORP earns 11.0% ROIC, Top 25% in Healthcare

ROIC TTM 11.0%, sector median -5.0%, Top 25%. DuPont: NOPAT margin 18.8% × asset turnover 0.5x. Gross margin 69.9%. Operating margin 19.8%. Source: 10-Q filed 2025-11-03.

Metric	BSX	Rating	Context
Return on Invested Capital (ROIC)	11.0%	Adequate	Above sector median of -5.0%
Return on Equity (ROE)	15.1%	Good	Efficient use of shareholder equity
Gross Margin	69.9%	Excellent	Strong pricing power
Operating Margin	19.8%	Good	Efficient operations

---

Cash Flow: BOSTON SCIENTIFIC CORP generates $3.6B FCF at 17.3% margin, positive NaN/8 quarters

FCF TTM $3.6B. FCF margin 17.3%, Top 5%. OCF/Net income 1.2x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-11-03.

Metric	BSX	Rating	Context
Free Cash Flow Margin	17.3%	Good	Excellent cash conversion
Free Cash Flow (TTM)	$3.6B	Good	Positive cash generation
OCF/Net Income	1.2x	Excellent	High earnings quality
FCF Consistency (8Q)	N/A	Warning	Variable cash flow

---

Balance Sheet: BOSTON SCIENTIFIC CORP at 0.5x leverage

Debt/Equity 0.5x. Total debt $12.6B, cash & investments $539.0M. Source: 10-Q filed 2025-11-03.

Metric	BSX	Rating	Context
Debt to Equity	0.5x	Good	Moderate leverage
Net Cash Position	$-12.1B	Warning	Net debt position

---

Valuation: BOSTON SCIENTIFIC CORP trades at 17.2x earnings

P/E 17.2x. EV/Sales 6.3x. FCF yield 5.7%. Source: 10-Q filed 2025-11-03.

Metric	BSX	Rating	Context
P/E Ratio	17.2x	Adequate	Reasonable valuation
EV/Sales	6.3x	Adequate	Growth premium priced in
FCF Yield	5.7%	Good	Attractive cash return

---

Capital Allocation: BOSTON SCIENTIFIC CORP returns 0.0% shareholder yield

Total shareholder yield 0.0%. Capital returned $0 TTM. Source: 10-Q filed 2025-11-03.

Metric	BSX	Rating	Context
Total Shareholder Yield	0.0%	Warning	Dividend + buyback yield combined
Total Capital Returned (TTM)	$0	Adequate	Dividends + buybacks returned to shareholders

---

Sector Rankings

Metric	Value	Percentile	vs Median
Return on Invested Capital (ROIC)	11.0%	Top 25%	-
Free Cash Flow Margin	17.3%	Top 5%	-
Gross Margin	69.9%	Top 50%	1.1x above
Operating Margin	19.8%	Top 25%	8.9x above
Return on Equity (ROE)	15.1%	Top 25%	-
P/E Ratio	17.2x	N/A	-

---

Financial Scorecard

Metric	BSX	Rating	Sector Context
Return on Invested Capital (ROIC)	11.0%	Adequate	Top 25% of sector (median: -5.0%)
Free Cash Flow Margin	17.3%	Good	Top 5% of sector (median: 0.0%)
Gross Margin	69.9%	Excellent	Top 50% of sector (median: 64.6%)
Debt to Equity Ratio	50.6%	Good	Moderate leverage
P/E Ratio (Price-to-Earnings)	17.2x	Adequate	Fair value
Free Cash Flow Yield	5.7%	Good	Solid cash yield

---

Frequently Asked Questions

Q: What is BOSTON SCIENTIFIC CORP's Return on Invested Capital (ROIC)?

BOSTON SCIENTIFIC CORP (BSX) has a trailing twelve-month Return on Invested Capital (ROIC) of 11.0%. Sector median -5.0%. Source: 10-Q filed 2025-11-03.

Q: What is BOSTON SCIENTIFIC CORP's Free Cash Flow Margin?

BOSTON SCIENTIFIC CORP (BSX) has a free cash flow margin of 17.3%, generating $3.6 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-11-03.

Q: What is BOSTON SCIENTIFIC CORP's P/E ratio and how does it compare to peers?

BOSTON SCIENTIFIC CORP (BSX) trades at a P/E ratio of 17.2x, which is above the sector median of N/A. EV/Sales 6.3x. FCF yield 5.7%. Source: 10-Q filed 2025-11-03.

Q: How much debt does BOSTON SCIENTIFIC CORP have?

BOSTON SCIENTIFIC CORP (BSX) has a debt-to-equity ratio of 0.5x with total debt of $12.6 billion. Net debt $12.1 billion. Source: 10-Q filed 2025-11-03.

Q: What is BOSTON SCIENTIFIC CORP's revenue and earnings growth?

BOSTON SCIENTIFIC CORP (BSX) grew revenue by 13.5% year-over-year. EPS +46.8% YoY. Source: 10-Q filed 2025-11-03.

Q: How does BOSTON SCIENTIFIC CORP compare to competitors in Healthcare?

Compared to other companies in Healthcare, BOSTON SCIENTIFIC CORP (BSX) shows: ROIC 11.0%, sector median -5.0% (Top 25%). FCF margin 17.3%, sector median 0.0% (Top 5%). Gross margin 69.9%, 5.4pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.

Q: What warning signs should I watch for with BOSTON SCIENTIFIC CORP?

No quantitative warning flags fired for BOSTON SCIENTIFIC CORP (BSX) on margin trend, FCF trend, ROIC trend, or leverage thresholds. Source: 10-Q filed 2025-11-03.

---

Data Source: Data sourced from 10-Q filed 2025-11-03. TTM metrics as of Q2 2026.

Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.

Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.

This analysis is for informational purposes only and does not constitute investment advice.